Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Prometheus Laboratories, Inc.

Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma


Release Date: June 30, 2019
Expiration Date: June 30, 2020
Media: Internet - based

Activity Overview

This program is designed to help you provide the best care possible for your patients with advanced renal cell carcinoma (RCC). In this enduring CME activity, Robert A. Figlin, MD, FACP, Laura S. Wood, RN, MSN, OCN, Julia A. Batten, APRN, Virginia J. Seery, MSN, RN, ANP-BC review the biology underpinning new therapies, clinical data leading to recent and anticipated approvals, and factors that influence overall treatment planning. Additionally, faculty will review and discuss best practices with respect to recognizing, mitigating, and managing adverse events associated with targeted therapies and immunotherapy. Cases will be used to illustrate will illustrate how to apply new standards of care to your practice and provide expert perspectives on areas of uncertainty. Be sure to join us for this exciting discussion of up-to-date clinical strategies for your patients with RCC.

Benefits of Participating

  • Gain insights into the mechanisms of action of new agents for patients with RCC
  • Improve your knowledge of key clinical data supporting the use of targeted agents and immunotherapy in RCC
  • Learn how to diagnose and manage treatment-related adverse events
  • Recognize patient and disease characteristics influencing choice of therapy through multiple lines of therapy

CME Activity Table of Contents

  • Pretest
  • The Current Therapeutic Landscape for Advanced/Metastatic Renal Cell Carcinoma
  • Case 1: Treatment Considerations for a patient With Metastatic Recurrence of Renal Cell Carcinoma
  • Case 2: Treatment Considerations for a Patient With De Novo Metastatic Renal Cell Carcinoma and Favorable Risk
  • Case 3: Management of Immune-Related Adverse Events in a Patient Receiving Immunotherapy-Based Combination Therapy
  • Case 4: Management of Gastrointestinal Toxicity in a Patient With Metastatic Renal Cell Carcinoma
  • Posttest and evaluation

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Prometheus Laboratories, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational program is directed toward nurse practitioners, nurses, and physicians involved in the treatment of patients with RCC. Other healthcare professionals with an interest in the treatment of RCC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Report the rationale underlying the use of targeted agents and immunotherapies, as single agents and in combination, for advanced RCC.
  • Discuss recent evidence concerning the use of state-of-the art strategies used to treat patients with RCC.
  • Apply best practices to proactively monitor for, recognize, and mitigate treatment-related toxicities related to targeted therapies and immunotherapies used to treat advanced RCC.
  • Explain factors that influence individualized advanced RCC treatment planning in the context of counseling strategies that may be utilized in these care settings.

Faculty, Staff, and Planners’ Disclosures

Faculty

Robert A. Figlin
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences Director,
Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant Research Support: Peloton, Bristol-Myers Squibb, Merck, Exelixis, Calithera; Consultant: Pfizer, Eisai.

Laura S. Wood
Laura S. Wood, RN, MSN, OCN
Renal Cancer Research Coordinator Cleveland
Clinic Taussig Cancer Center
Cleveland, OH

Disclosures: Grant Research Support: Merck; Speakers Bureau: Bristol-Myers Squibb, Pfizer.

Virginia J. Seery
Virginia J. Seery, MSN, RN, ANP-BC
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Grant Research Support: Apricity Health.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

PER Pulse Recaps

1 of 3

Insights from Robert A. Figlin, MD, FACP; Virginia J. Seery, MSN, RN, ANP-BC; and Laura S. Wood, RN, MSN, OCN – PER Pulse™ Recap:
Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma

Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma is a series of short video interviews with faculty who address questions commonly faced by practicing oncology nursing professionals via discussions of clinical vignettes. The activity features discussions on:

  • The Current Therapeutic Landscape for Advanced/Metastatic Renal Cell Carcinoma (RCC)
  • Case 1: Treatment Considerations for a Patient With Metastatic Recurrence of RCC
  • Case 2: Treatment Considerations for a Patient With De Novo Metastatic RCC and Favorable Risk
  • Case 3: Management of Immune-Related Adverse Events (AEs) in a Patient Receiving Immunotherapy-Based Combination Therapy
  • Case 4: Management of Gastrointestinal Toxicity in a Patient With Metastatic RCC

Throughout the activity, these experts answer questions about their decisions for case management and offer their perspectives and guidance on issues important to community-based health care providers.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on the faculty’s answers to questions about the treatment of metastatic recurrent RCC. During this activity, the faculty:

  • Discuss their approach for a 56-year-old favorable-risk male patient who, after nephrectomy 2 years ago for treatment of clear-cell RCC, presented with metastatic RCC. After receiving sunitinib, he developed treatment-related hand-foot syndrome and relapsed 6 months later.
  • Share their perspectives on a variety of treatment-related issues, including using risk assessment to choose the best therapeutic options, and the role of supportive care, dose modifications, and patient counseling to manage treatment-related adverse effects.
  • Review second-line treatment options after a first-line tyrosine kinase inhibitor (TKI), as well as best practices for applying emerging therapeutic options in the second line, including combination TKI and immune checkpoint inhibitor treatment.

“About 20% of our patients [with RCC] are what are called favorable risk, and when we think about favorable-risk patients [with metastatic RCC], we think about a spectrum of opportunities—older opportunities like high-dose interleukin-2, newer opportunities like targeted therapy, and even newer opportunities like immunotherapy approaches either alone or in combination, and lastly, clinical trials.”
— Robert A. Figlin, MD, FACP


2 of 3

Insights from Robert A. Figlin, MD, FACP, and Virginia J. Seery, MSN, RN, ANP-BC – PER Pulse™ Recap:
Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma

Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma is a series of short video interviews with faculty who address questions commonly faced by practicing community oncology nursing professionals via discussions of clinical vignettes. The activity features discussions on:

  • The Current Therapeutic Landscape for Advanced/Metastatic Renal Cell Carcinoma (RCC)
  • Case 1: Treatment Considerations for a Patient With Metastatic Recurrence of RCC
  • Case 2: Treatment Considerations for a Patient With De Novo Metastatic RCC and Favorable Risk
  • Case 3: Management of Immune-Related Adverse Events (AEs) in a Patient Receiving Immunotherapy-Based Combination Therapy
  • Case 4: Management of Gastrointestinal Toxicity in a Patient With Metastatic RC

Throughout the activity, these experts answer questions about their decisions for case management and offer their perspectives and guidance on issues important to community-based health care providers.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on the faculty’s answers to questions about treatment considerations for de novo metastatic RCC in a favorable-risk patient. During this activity, the faculty:

  • Discuss their initial treatment approach for a 65-year-old favorable-risk male patient with a 10-cm left renal mass and a 2-cm right middle lobe mass, including the role of radical nephrectomy in good-risk patients with metastatic RCC and how to apply data from the phase III CARMENA trial of sunitinib with or without nephrectomy in patients with metastatic RCC
  • Review factors that influence treatment decision making in this patient population, such as performance status, existing comorbidities, and patient preference
  • Share their thoughts on how best to counsel patients on starting a targeted agent or immunotherapy, such as monitoring for potential AEs and encouraging good communication with the health care team

“The results of [the CARMENA] trial demonstrated that cytoreductive nephrectomy didn’t seem to be helpful and, in fact, was somewhat harmful. But the data [were] primarily in intermediate- and poor-risk patients. So, while CARMENA helps us navigate through the appropriate use of cytoreductive nephrectomy in certain populations, it doesn’t answer [our questions] for all populations.”
— Robert A. Figlin, MD, FACP


3 of 3

Insights from Robert A. Figlin, MD, FACP; Virginia J. Seery, MSN, RN, ANP-BC; and Laura S. Wood, RN, MSN, OCN – PER Pulse™ Recap:
Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma

Community Practice Connections™: Nursing Essentials: Optimized Care Strategies for the Patient With Advanced Renal Cell Carcinoma is a series of short video interviews with faculty who address questions commonly faced by practicing oncology nursing professionals via discussions of clinical vignettes. The activity features discussions on:

  • The Current Therapeutic Landscape for Advanced/Metastatic renal cell carcinoma (RCC)
  • Case 1: Treatment Considerations for a Patient With Metastatic Recurrence of RCC
  • Case 2: Treatment Considerations for a Patient With De Novo Metastatic RCC and Favorable Risk
  • Case 3: Management of Immune-Related Adverse Events (irAEs) in a Patient Receiving Immunotherapy-Based Combination Therapy
  • Case 4: Management of Gastrointestinal Toxicity in a Patient With Metastatic RCC

Throughout the activity, these experts answer questions about their decisions for case management and offer their perspectives and guidance on issues important to community-based health care providers.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on the faculty’s answers to questions about management of irAEs associated with immunotherapy-based combination therapy. During the interview, the faculty:

  • Discuss their approach for a 65-year-old female patient undergoing treatment with ipilimumab plus nivolumab for metastatic RCC who is experiencing treatment-related diarrhea.
  • Share their perspectives on how AE management would be tailored for patients receiving immunotherapy combinations versus immunotherapy plus a VEGF tyrosine kinase inhibitor
  • Review how they use would use steroids for a patient with treatment-related diarrhea and an increasing creatinine level

“It’s important to recognize that once you’ve given another dose of immunotherapy, you can’t take it back. You have initiated a progression of the immune system being jump-started, and you can’t reverse that unless you give steroids. So [in the presence of treatment-related diarrhea], it’s always smarter to hold therapy and obtain additional information…to make sure you’ve got a complete picture.”
— Laura S. Wood, RN, MSN, OCN


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By